BCR/ABL amplification in CML blast crisis following STI571 administration.

被引：0
作者：
Campbell, LJ
Patsouris, C
Rayeroux, KC
Somana, K
Januszewicz, H
机构：
[1] St Vincents Hosp, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4435
引用
收藏
页码：185B / 185B
页数：1
相关论文
共 50 条
  • [21] The rationale engineering of BCR/ABL blockers: an answer to STI571 acquired resistance in leukemia treatment
    Majsterek, IJ
    LEUKEMIA RESEARCH, 2005, 29 (06) : 605 - 606
  • [22] Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571
    Nimmanapalli, R
    Bhalla, K
    ONCOGENE, 2002, 21 (56) : 8584 - 8590
  • [23] STI571 removal induces apoptosis in BaF/BCR-ABL resistant cell lines
    Desplat, V
    Belloc, F
    Lagarde, V
    Melo, JV
    Reiffers, J
    Mahon, FX
    7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, : 123 - 127
  • [24] Clinical activity of an ABL-tyrosine kinase inhibitor (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
    Wassmann, B
    Scheuring, U
    Thiede, C
    Bornhäuser, M
    Griesinger, F
    Petershofen, E
    Gschaidmeier, H
    Capdeville, R
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2000, 96 (11) : 218B - 218B
  • [25] Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571
    Tabrizi, R
    Mahon, FX
    Makhoul, PC
    Lagarde, V
    Lacombe, F
    Berthaud, P
    Melo, JV
    Reiffers, J
    Belloc, F
    LEUKEMIA, 2002, 16 (06) : 1154 - 1159
  • [26] Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571
    R Tabrizi
    FX Mahon
    P Cony Makhoul
    V Lagarde
    F Lacombe
    P Berthaud
    JV Melo
    J Reiffers
    F Belloc
    Leukemia, 2002, 16 : 1154 - 1159
  • [27] Effects of Glivec® (fomerly STI571) alone and in combination with α-IFN and Ara-C on the amount of BCR/ABL transcript in CML cells.
    Ottaviani, E
    Giannini, B
    Amabile, M
    Martinelli, G
    Bonifazi, F
    Zardini, C
    Grafone, T
    Trabacchi, E
    Bassi, S
    Rosti, G
    Terragna, C
    Buonamici, S
    Soverini, S
    De Vivo, A
    Alberti, D
    Tura, S
    Baccarani, M
    BLOOD, 2001, 98 (11) : 265B - 265B
  • [28] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response to STI571 in chronic phase CML patients.
    Merx, K
    Kreil, S
    Lahaye, T
    Müller, MC
    Paschka, P
    Schoch, C
    Weisser, A
    Kuhn, C
    Landmann, T
    Gschaidmeier, H
    Berger, U
    Hehlmann, R
    Hochhaus, A
    BLOOD, 2001, 98 (11) : 846A - 847A
  • [29] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)
    Thiele J.
    Kvasnicka H.M.
    Varus E.
    Kriener S.
    Engels K.
    Staib P.
    Ollig E.S.
    Griesshammer M.
    Waller C.F.
    Pfeifer H.
    Schmitt-Gräff A.
    Der Pathologe, 2004, 25 (6): : 428 - 435
  • [30] Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
    Weisberg, E
    Griffin, JD
    BLOOD, 2000, 95 (11) : 3498 - 3505
12345